Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer

被引:40
作者
Kefeli, U.
Dane, F.
Yumuk, P. F. [1 ]
Karamanoglu, A. [2 ]
Iyikesici, S.
Basaran, G.
Turhal, N. S.
机构
[1] Marmara Univ, Sch Med, Dept Internal Med, Div Med Oncol, Istanbul, Turkey
[2] Marmara Univ, Med Sch Hosp, Gul Genc Outpatient Therapy Ctr, Istanbul, Turkey
关键词
catheters; indwelling; catheterization; central venous; neoplasms; heparin; venous thrombosis; CENTRAL VENOUS CATHETERS; MOLECULAR-WEIGHT HEPARIN; ACCESS DEVICES; PREVENTION; COMPLICATIONS; THROMBOSIS; TRIAL; UROKINASE; WARFARIN; CHILDREN;
D O I
10.1111/j.1365-2354.2008.00973.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The long-term use of subcutaneous implanted ports for chemotherapy in cancer patients has been associated with the occurrence of thrombosis and infection. In this study, we compared the safety and efficacy of administration of 1000 U of heparin flushes in prolonged interval (every 6 weeks) with standard dose and schedule (500 U every 4 weeks) for port-related infections and thrombosis during periods of non-use. Data were collected retrospectively from patients treated for various cancer types (matched as 2: 1 for age, gender, stage of the disease). Patients who had diseases that could cause thrombosis or bleeding in their past medical history, or were taking oral anticoagulants, or had contraindications for heparin usage were excluded. After completing their chemotherapy, 59 patients received prolonged interval, while 30 patients received standard schedule. All patients were followed for at least 1 year. No clinically documented port-related infection or thrombosis has been found in both groups. Also, none of the devices was removed during this time. Prophylactic flushing of central venous ports with 1000 U of heparin in every 6 weeks might be a safe, easy, cheaper, comfortable and effective alternative to standard dose and schedule for preventing thrombosis and infections.
引用
收藏
页码:191 / 194
页数:4
相关论文
共 23 条
[11]   An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial [J].
Massicotte, P ;
Julian, JA ;
Gent, M ;
Shields, K ;
Marzinotto, V ;
Szechtman, B ;
Chan, AK ;
Andrew, M .
THROMBOSIS RESEARCH, 2003, 109 (2-3) :101-108
[12]  
Mismetti P, 2003, HAEMATOLOGICA, V88, P67
[13]  
Monreal M, 1996, THROMB HAEMOSTASIS, V75, P251
[14]   Guidelines for the prevention of intravascular catheter-related infections [J].
O'Grady, NP ;
Alexander, M ;
Dellinger, P ;
Gerberding, JL ;
Heard, SO ;
Maki, DG ;
Masur, H ;
McCormick, RD ;
Mermel, LA ;
Pearson, ML ;
Raad, II ;
Randolph, A ;
Weinstein, RA .
PEDIATRICS, 2002, 110 (05)
[15]  
PAZDUR R, 2005, MED SURG RAD ONCOLOG, P935
[16]   Benefit of heparin in central venous and pulmonary artery catheters - A meta-analysis of randomized controlled trials [J].
Randolph, AG ;
Cook, DJ ;
Gonzalez, CA ;
Andrew, M .
CHEST, 1998, 113 (01) :165-171
[17]   Weekly prophylactic urokinase instillation in tunneled central venous access devices [J].
Ray, CE ;
Shenoy, SS ;
McCarthy, PL ;
Broderick, KA ;
Kaufman, JA .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1999, 10 (10) :1330-1334
[18]   COMPLICATIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS - A SURVEY [J].
SCOTT, WL .
CHEST, 1988, 94 (06) :1221-1224
[19]   Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin [J].
Solomon, B ;
Moore, J ;
Arthur, C ;
Prince, HM .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (18) :2379-2384
[20]  
Taber S W, 1997, Semin Vasc Surg, V10, P130